About 5 results found for searched term "Sorafenib-d3" (0.125 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M57288 | Sorafenib-d3 | Raf |
| Donafenib; Bay 43-9006-d3 | ||
| Sorafenib-d3 (Donafenib) is a deuterium-labeled Sorafenib, it is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. | ||
| M1827 | Sorafenib Tosylate | VEGFR/PDGFR |
| BAY 43-9006,Nexavar | ||
| Sorafenib (BAY 43-9006) Tosylate is an orally active multikinase inhibitor of tyrosine protein kinases VEGFR/PDGFR and RAF/MEK/ERK with IC50 values of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. | ||
| M3026 | Sorafenib (BAY 43-9006) | Raf |
| BAY 43-9006 | ||
| Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. Sorafenib is a multikinase inhibitor with IC50 values of 15 nM, 20 nM, 57 nM and 58 nM for VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib is a ferroptosis activator. | ||
| M11331 | UC2288 | Mdm2 |
| UC2288 is a novel p21 attenuator with cellular permeability and oral activity (relatively selective activity for P21), based on the structural synthesis of sorafenib. UC2288 down-regulated the expression of P21 mRNA and reduced the level of P21 protein independently of p53, and had little effect on the stability of P21 protein. UC2288 did not inhibit VEGFR2 and Raf kinases, even at 10 μM. | ||
| M56429 | 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea | STAT |
| STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
